2024-511051-18-00CompletedPhase 1
A Randomized, Blinded, Placebo-Controlled Dose-Ranging Phase 1b Study of the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects with Chronic Hepatitis B Virus Infection
Source: EU CTIS (euclinicaltrials.eu) · Last updated 26 Sept 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- First submitted
- 23 Apr 2024
- Start date
- 6 Aug 2024
- Lead sponsor
- Assembly Biosciences Inc.
- Diseases
- Hepatitis B
- EU CT number
- 2024-511051-18-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 22
- 3 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Multiprofile Hospital for Active Treatment Sveta Sofia | Sofiya | Bulgaria | Completed |
| Institutul National de Boli Infectioase "Prof.Dr. Matei Bals" | Bucharest | Romania | Completed |
| Spitalul Clinic Judetean De Urgenta Cluj | Cluj-Napoca | Romania | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.